While normal cells can rely on multiple NAD biosynthetic pathways, cancer cells that have transitioned to a mesenchymal phenotype often lose NAPRT expression, typically via promoter hypermethylation or aberrant transcription initiation, thereby becoming critically dependent on NAMPT activity for survival. Here, NAPRT is linked to cancer.